MAAB Inc.

What MAAB Inc. does

MAAB Inc. (operating as MAAB Group) is a privately held boutique healthcare investment and commercialisation platform founded in 2011 by pharmaceutical industry veterans. Originally incorporated in Hong Kong, the group is now headquartered in Auckland, New Zealand, and operates through five wholly-owned subsidiaries across mainland China (Shanghai MAAB Trading, Nantong-based MAAB Universal Pharma manufacturing), the United Kingdom (MAAB Pharma, RD Biomed at the University of Hull), and Denmark (MAAB ApS). Its core function is to bridge Western pharmaceutical, medical technology, and digital health innovation with Asia — particularly China — by sourcing in-licensed assets, navigating local regulatory and pharmacoeconomic frameworks, providing advisory and licensing facilitation, and delivering localised manufacturing and commercialisation.

The company's product and service portfolio spans five therapeutic areas (reflux, oncology supportive care, neurology, dermatology, and probiotics/microbiome) and three service lines (healthcare algorithm development, sustainable and RFID-enabled packaging, and reference medicine sourcing). Branded products include Sancuso (granisetron transdermal patch for CINV, exclusively licensed from Solasia for Greater China), ClearSky (digital platform for neurodegenerative diseases), EcoVag (OTC women's health probiotic), Peptest (non-invasive reflux diagnostic), TrueTest and Finn Chamber (skin allergy patch testing), and MAAB Probiotics. The technology stack combines ML/AI services for clinical decision support, RFID traceability packaging, and cross-border pharmaceutical distribution systems anchored by the Nantong manufacturing facility.

MAAB monetises through a hybrid revenue model: licensing royalties and exclusive commercialisation rights (Sancuso), professional services fees (Asia advisory, healthcare algorithm development, packaging solutions), and transaction-based reference medicine sourcing. Go-to-market is sales-led enterprise with channel partners, targeting pharmaceutical and medical technology innovators seeking to enter China and Australasia, as well as Western asset holders pursuing licensing, distribution, or divestment of China assets. Pricing is bespoke and quote-based. Disclosed customers include 3M, BD, and Galderma (packaging), Solasia (Sancuso licensing), and The Reflux Company (strategic advisory and seed co-investment, MAAB's first US engagement). The company is founder-controlled, with no disclosed institutional investors, parent company, or public listing.

Name

MAAB Inc.

Legal name

MAAB International Limited

Website

https://maab-group.com

Company type

Private

Founded year

2011

Operating status

Operating

Short description

MAAB Group is a private New Zealand-headquartered healthcare investment and commercialisation platform that in-licenses Western pharmaceutical, diagnostic, and digital health products and brings them to China and Australasia via advisory, licensing, manufacturing, and distribution services.

Ownership category

akta.pro rank

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. International Licensing Deals: Facilitation of international licensing agreements for pharmaceutical and medical technology innovators, leveraging expertise in sourcing, legal and regulatory intricacies, and import/export logistics between China and UK/Europe.
2. Strategic Advisory Services: Advisory services for Asia market entry, including market access, regulatory strategy, commercialisation, distribution network development, and strategic partnerships in China.
3. Healthcare Algorithm Development: Custom algorithm development and machine learning solutions for neurological disease diagnosis and monitoring.
4. Packaging Solutions: Sustainable packaging, RFID healthcare packaging, and end-to-end packaging services for healthcare and other industries.
5. Reference Medicine Sourcing: Sourcing service for reference medicines for clinical trials, pharmaceutical research, and patient treatment.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

MAAB Group is a boutique healthcare investment and trading company that commercialises innovative medical products internationally, with a particular focus on bridging Western healthcare innovation with Asian markets (Greater China and Australasia). The company facilitates cross-border licensing deals, advises on regulatory strategy, provides packaging solutions, and supplies reference medicines, alongside distributing its own portfolio of medical products (including Sancuso, Peptest, Ecovag, Finn Chamber, and ClearSky digital diagnostic platform).

Product overview

MAAB Group is a boutique healthcare investment and commercialisation platform that commercialises pioneering medical products globally or regionally in China, Australia, and New Zealand. The portfolio includes pharmaceutical products (SANCUSO - a transdermal patch for CINV; ECOVAG - OTC probiotics for women's health), diagnostic tests (PEPTEST - non-invasive reflux test; TRUETEST and FINN CHAMBER - patch testing tools), digital health technology (CLEARSKY - neurodegenerative disease technology; Healthcare Algorithm services with custom ML/AI solutions), and probiotic products (MAAB PROBIOTICS). The company also offers services including packaging solutions (sustainable, RFID-enabled), international licensing deals facilitation, and reference medicine sourcing. The products work across therapeutic areas including reflux disease, cancer care, neurological AI, skin allergies, and probiotics/microbiome.

Differentiator

Problem solved

Functional benefit

Brands

• MAAB Probiotocs: Evidence-based probiotic products commercialised globally or regionally in China, Australia and New Zealand.
• ClearSky
• EcoVag

Products and services

• SANCUSO SANCUSO is a transdermal patch product for the prevention of chemotherapy-induced nausea and vomiting; MAAB holds commercialisation rights for Greater China.
• CLEARSKY ClearSky is a digital technology platform that uses proprietary algorithms for diagnosis and monitoring of neurodegenerative diseases; available to healthcare providers and clinical researchers.
• ECOVAG Ecovag is an over-the-counter probiotic product for vaginal health, distributed through pharmacy and consumer health channels.
• FINN CHAMBER Finn Chamber is a patch testing tool used by dermatologists and allergists for allergy diagnosis.
• PEPTEST Peptest is a non-invasive diagnostic test for detecting reflux (pepsin in saliva); sold to clinicians and patients in Greater China and Australasia.
• MAAB PROBIOTICS Branded probiotic product line distributed by MAAB through its regional healthcare channels.
• TRUETEST TrueTest is a patch test panel system for dermatological allergy testing.
• International Licensing Deal Facilitation Boutique advisory and deal-structuring service that helps Western pharmaceutical and medical technology innovators secure licensing, distribution, and commercialisation partners in Greater China and Australasia.
• Packaging Solutions Specialised pharmaceutical and healthcare packaging services including RFID and sustainable packaging formats, supplied to pharmaceutical manufacturers.
• Reference Medicine Sourcing Service Sourcing and supply service for reference medicines (clinical trial materials) provided to pharmaceutical companies and clinical trial sponsors in the Asia-Pacific region.
• Healthcare Algorithm Development Services Bespoke development of AI/ML diagnostic algorithms for healthcare and pharmaceutical clients, extending the capabilities behind the ClearSky platform.

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• The Reflux CompanycoreStrategic or Co-development Partner · 1 April 2026MAAB Group has entered into a strategic partnership with The Reflux Company, participating in its oversubscribed seed funding round. MAAB has been appointed as the official advisory service for Asia with primary focus on China. The partnership covers market access and regulatory strategy, commercialisation and distribution network development, strategic partnerships in China, and ongoing fundraising and expansion initiatives. The Reflux Company is building a global platform focused on diagnosis and treatment of reflux-related diseases including LPR and GERD, with products spanning diagnostic tools (Dx-pH™), minimally invasive therapies (Stretta®), and patient-centric solutions (Reflux Band®, PepsinCheck™). This represents MAAB's first strategic engagement in the United States.
• SolasiacoreOEM/ Whitelabel/ Licensing Partner · 1 January 2026MAAB Group announced a strategic licensing agreement with Solasia to bring Sancuso® (granisetron transdermal system) across Greater China. MAAB assumes exclusive manufacturing and commercialisation rights for Sancuso® in the region, with plans to establish local production capacity in China. The partnership covers Mainland China, Hong Kong, Macau, and Taiwan. Sancuso® is a transdermal patch delivering granisetron to prevent chemotherapy-induced nausea and vomiting (CINV), with regulatory approvals from U.S. FDA, EMA, and China's NMPA. This marks MAAB's strategic entry into oncology supportive care.
• 3MminorChannel Partner/ Reseller/ Distributor3M is listed as a client for MAAB Group's packaging solutions services.
• BDminorChannel Partner/ Reseller/ DistributorBD (Becton Dickinson) is listed as a client for MAAB Group's packaging solutions services.
• GaldermaminorChannel Partner/ Reseller/ DistributorGalderma is listed as a client for MAAB Group's packaging solutions services.
• RD Biomed LimitedminorStrategic or Co-development PartnerUK-based operations partner located at the University of Hull, supporting MAAB's European operations and healthcare technology initiatives.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hutchmed (China) Limited: Innovative biopharma commercialising oncology and immunology drugs in China and globally with strong regulatory and distribution capabilities. Comparable in China-centric commercialisation strategy.
• LianBio: Cayman-incorporated clinical-stage biopharma partnering with Western innovators for China development and commercialisation. Comparable boutique cross-border model and therapeutic focus.
• China Pioneer Pharma Holdings: Hong Kong-listed cross-border pharmaceutical distribution and commercialisation company focused on bringing Western drugs into China. Closely comparable to MAAB's licensing-and-distribution model, though operating at significantly larger scale.
• China Medical System Holdings: China-focused pharmaceutical commercialisation and distribution platform with a similar model of in-licensing and marketing Western drugs to Chinese hospitals and pharmacies. Comparable on business model and customer base.
• Zai Lab: US-listed China-focused biopharma that licenses and commercialises innovative drugs from global partners for Greater China. Closely aligned with MAAB's cross-border licensing bridge, though focused on development-stage assets.

Emerging players

• Yidu Tech: China-based healthcare AI and data analytics company with algorithmic diagnostic capabilities. Comparable on the AI/algorithm-for-clinical-use overlap with MAAB's ClearSky and algorithm services.
• Antengene Corporation: Asia-Pacific focused clinical-stage biopharma commercialising innovative oncology therapies. Comparable cross-border model and therapeutic-area focus, but earlier stage.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO giant with end-to-end discovery, development, and manufacturing services across therapeutics. Comparable in cross-border healthcare services but vastly larger and broader in scope.
• Tigermed: Large Chinese CRO/CDMO offering clinical development, regulatory, and commercialisation services to global biopharma. Comparable as a one-stop cross-border partner but operates at much larger scale.
• Schott Pharma: Global specialty pharma packaging supplier serving major biopharma companies. Comparable on the high-quality, RFID-enabled pharma packaging overlap with MAAB's packaging services line.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubestudio.youtube.com/channel/UCD6FgY4RfDtvXILozdwJYPg
• Facebookfacebook.com/MAABProbi
• LinkedInlinkedin.com/company/maab-group
• Instagraminstagram.com/maabprobi

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MAAB Inc.